Rifaximin Exerts Beneficial Effects Independent of its Ability to Alter Microbiota Composition by Kang, Dae J et al.
Rifaximin Exerts Beneficial Effects Independent of its
Ability to Alter Microbiota Composition
Dae J. Kang, MS1, Genta Kakiyama, PhD1, Naga S. Betrapally, MS2, Jeremy Herzog, BS3, Hiroshi Nittono, MD4, Phillip B. Hylemon, PhD5,
Huiping Zhou, PhD5, Ian Carroll, PhD2, Jing Yang, BS5, Patrick M. Gillevet, PhD2, Chunhua Jiao, MS5, Hajime Takei, PhD4,
William M. Pandak, MD1, Takashi Iida, PhD6, Douglas M. Heuman, MD1, Sili Fan, MS7, Oliver Fiehn, PhD7, Takao Kurosawa, PhD8,
Masoumeh Sikaroodi, PhD2, R.B. Sartor, MD3,9 and Jasmohan S. Bajaj, MD1,9
OBJECTIVES: Rifaximin has clinical benefits in minimal hepatic encephalopathy (MHE) but the mechanism of action is unclear. The
antibiotic-dependent and -independent effects of rifaximin need to be elucidated in the setting of MHE-associated microbiota. To
assess the action of rifaximin on intestinal barrier, inflammatory milieu and ammonia generation independent of microbiota using
rifaximin.
METHODS: Four germ-free (GF) mice groups were used (1) GF, (2) GF+rifaximin, (3) Humanized with stools from an MHE patient,
and (4) Humanized+rifaximin. Mice were followed for 30 days while rifaximin was administered in chow at 100 mg/kg from days
16–30. We tested for ammonia generation (small-intestinal glutaminase, serum ammonia, and cecal glutamine/amino-acid
moieties), systemic inflammation (serum IL-1β, IL-6), intestinal barrier (FITC-dextran, large-/small-intestinal expression of IL-1β,
IL-6, MCP-1, e-cadherin and zonulin) along with microbiota composition (colonic and fecal multi-tagged sequencing) and function
(endotoxemia, fecal bile acid deconjugation and de-hydroxylation).
RESULTS: All mice survived until day 30. In the GF setting, rifaximin decreased intestinal ammonia generation (lower serum ammonia,
increased small-intestinal glutaminase, and cecal glutamine content) without changing inflammation or intestinal barrier function.
Humanized microbiota increased systemic/intestinal inflammation and endotoxemia without hyperammonemia. Rifaximin therapy
significantly ameliorated these inflammatory cytokines. Rifaximin also favorably impactedmicrobiota function (reduced endotoxin and
decreased deconjugation and formation of potentially toxic secondary bile acids), but not microbial composition in humanized mice.
CONCLUSIONS: Rifaximin beneficially alters intestinal ammonia generation by regulating intestinal glutaminase expression
independent of gut microbiota. MHE-associated fecal colonization results in intestinal and systemic inflammation in GF mice,
which is also ameliorated with rifaximin.
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INTRODUCTION
Modulating the gut milieu is a target for treatments that
ameliorate the systemic pro-inflammatory milieu in several
relevant human diseases such as hepatic encephalopathy
(HE), irritable bowel syndrome, and inflammatory bowel
diseases.1,2 Rifaximin, which is widely viewed as a non-
absorbable antibiotic, has clinical efficacy in improving out-
comes in humans with overt and minimal HE (MHE).3,4
Patients with MHE and overt HE have a combination of liver
disease, porto-systemic shunting, and systemic and intestinal
inflammation alongwith dysbiosis, which can negatively impact
prognosis and psycho-social functioning.5,6 Being a non-
absorbable compound, it is likely that the primary impact of
rifaximin is on the gut milieu with subsequent secondary
beneficial effects systemically.7 However, its modest impact on
bacterial composition raises questions whether an antibiotic
action is solely responsible for its mechanism of action.3,8
There is also emerging evidence that rifaximin could have
direct effects on intestinal barrier function and metabolomics,
which could add another facet to its action.9,10
We hypothesized that rifaximin beneficially impacts intest-
inal and systemic inflammation, and intestinal ammonia
generation independent of its activity on gut microbiota in
the setting of MHE-associated microbiota.
Our aim was to define the effect of rifaximin on intestinal
ammonia and amino-acid metabolism, intestinal barrier
function, dysbiosis, and ultimately on the systemic inflamma-
tory milieu in germ-free (GF) mice and humanized mice
(formerly GF mice colonized with a human fecal microbiota
from a patient with MHE), and determine if these activities
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were dependent on altering bacterial composition. Specifically
our focus was on defining the effect of rifaximin on MHE-
associated microbiota without concomitant cirrhosis.
METHODS
Rifaximin was provided by Valeant Pharmaceuticals (Bridge-
water, NJ) to theUniversity of North Carolina, and proven to be
tolerated by the mice at a dose of 100 mg/kg. The rifaximin
used was a water-soluble form that does not require bile acids
for solubility. For the study, we included sixteen 10–15-week
old C57BL/6 GF mice. All mice were kept under sterile
conditions in the National Gnotobiotic Rodent Resource
Center (NGRRC) eating their similar Harland2020 chow for
the 30 days of the study. Sterility was verified by fecal Gram
stain, and aerobic and anaerobic culture. Group 1 remained
GF, whereas Group 2 mice remained GF but were fed the
chow mixed with 100 mg/kg of rifaximin for the last 15 days.
Groups 3 and 4 were formerly GF mice that were humanized
(colonized with a human fecal microbiota) using stools from a
47–year-old man with eradicated hepatitis c virus cirrhosis
without prior decompensation or current/recent alcohol use.
The patient’s Model for End-Stage Liver Disease score at the
time of stool donation was 12, and he had evidence of MHE on
two separate testing modalities per AASLD/EASL guidelines:
a standardized paper-pencil cognitive battery (Psychometric
HE score was −8) and EncephalApp Stroop (OffTime
+OnTime: 214.55 s).11 His stool was mixed in phosphate-
buffered saline and granular material was removed and then
stored in several aliquots at − 80°C till the time of mouse
colonization. Several aliquots of the stool were tested with
respect to microbiota composition; the composition of fecal
microbiota did not cluster separately based on weighted
UNIFRAC distances (P=0.89) (http://qiime.org/tutorials/tutor-
ial.html). The microbiota composition was similar to a group of
78 cirrhotic patients without decompensation and significantly
different from that of healthy controls.2 Bacterial colonization
was performed by 3 days of rectal swabbing, inoculation of the
bedding, and orogastric gavage according to NGRRC
established protocols.12 Group 3 remained humanized for
30 days, whereas group 4 received rifaximin in their chow for
the last 15 days. All four groupswere kept in separate cages in
different Trexler isolators at the NGRRC to prevent cross-
contamination. All mice tolerated the procedures and did not
exhibit any behavioral or asthenic changes. Stools were
collected at day 30 from all mice. To determine in vivo
permeability of the mouse intestine mice were gavaged with
200 μl of a FITC-dextran solution (Sigma-Aldrich, St. Louis,
MO) at a concentration of 1 mg FITC-dextran/g of body weight.
Three hours later, at necropsy, blood was collected via cardiac
puncture. The amount of FITC-dextran in blood was deter-
mined using a fluorometer (SLM Amico SPF 500, SLM
Instruments, Urbana, IL) at 485 nm excitation and 530 nm
emission. Intestinal permeability was expressed as ng FITC-
dextran/ml of blood13. During necropsy blood and stool were
also collected.
Preparation of mice intestinal tissues. At necropsy, the
small and large intestine, and cecum were collected
immediately, cut into small pieces, and placed into pre-
labeled tubes. All intestinal samples were collected, snap-
frozen in liquid nitrogen and stored at − 80 °C until RNA was
isolated.
RNA isolation and analysis. Total RNA from mice tissues
was extracted and isolated using TRIzol reagent (Life
Technologies, Grand Island, NY) according to the manufac-
turer’s instructions. For quantitative real-time RT-PCR (q-
PCR), RNA was reverse-transcribed using the ThermoScript
RT-PCT system kit (Life Technologies) at 50 °C for 50 min.
cDNA was amplified and quantified using the SsoAdvanced
Universal SYBR Green Supermix (Bio-Rad, Hercules, CA)
according to the manufacturer’s instructions in the iQ5 real-
time PCR detection system (Bio-Rad) under the following
conditions: initial denaturation at 95 °C for 5 min, 40 cycles of
95 °C for 30 s, and 60 °C for 30 s. q-PCR was performed in
triplicate for each sample and repeated at least three times.
Ct values were used to calculate the relative expression level
normalized to the expression of GAPDH housekeeping gene.
A melting curve analysis was performed for each sample after
PCR amplification to verify that the amplicon is homogeneous
in the absence of primer dimmers and DNA contamination.
Microbiota assessment
Microbial composition. Stool and large-intestinal mucosal
microbiota composition was measured using validated
techniques of multi-tagged pyrosequencing.
Multitag sequencing. We interrogated the microbial taxa
associated with the gut microbiome using multitag sequen-
cing. This technique allows the rapid sequencing of multiple
samples at one time, yielding thousands of sequence reads
per sample.14 Specifically, we have generated a set of 96
emulsion PCR fusion primers that contain the Ion Torrrent
PGM linkers on the 27F primer (5′-AGAGTTTGATCCT
GGCTCAG-3′) and 355R′ (5′-GCTGCCTCCCGTAGGAG
T-3′) and different eight-base “barcode” between the A
adapter and the 27F primer. Thus each fecal sample was
amplified with unique barcoded forward 16S rRNA primers,
and then up to 96 samples were pooled and subjected to
emulsion PCR and sequenced using a Ion Torrent PGM
sequencer (Thermo-Fisher, Grand Island, NY). Data from
each pooled sample were “deconvoluted” by sorting the
sequences into bins based on the barcodes using custom
PERL scripts. Reads were filtered based on quality scores
and length. Thus, we normalized each sample by the total
number of reads from each barcode. We have noted that
ligating tagged primers to PCR amplicons distorts the
abundances of the communities, and thus it is critical to
incorporate the tags during the original amplification step.14
We identified the taxa present in each sample using the
Bayesian analysis tool in Version 10 of the Ribosomal
Database Project (RDP10). The abundances of the bacterial
identifications were then normalized using a custom PERL
script, and taxa present at 40.1% of the community were
tabulated. We chose this cutoff because of our a priori
assumption that taxa present in o0.1% of the community
vary between individuals and have minimal contribution to the
functionality of that community, and that 20,000 reads per
sample will only reliably identify community components that
are 40.1% in abundance. We used UNIFRAC QIIME
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analysis, and Linear discriminant analysis (LEFSe) to define
changes between groups 3 and 4 and the human donor stool
(http://qiime.org/tutorials/tutorial.html).15
Microbial function. We assessed microbial function using two
separate processes (a) serum endotoxin, which was eval-
uated using the limulus amebocyte lysate assay (Assaygate,
Ijamsville, MD)16 and (b) fecal bile acid (BA) modification.
Fecal BAs were quantitated by the LC-ESI-MS/MS technique
in Japan according to our previous report.17 Two major
processes undertaken by microbiota were studied: deconju-
gation from conjugated to de-conjugated BAs and the 7-α
de-hydroxylation from primary to secondary BAs. In the
present study, α,β-muricholic, hyocholic, cholic, chenodeoxy-
cholic acid were considered primary BAs. Muri-deoxycholic,
ω-muricholic, deoxycholic, and lithocholic acids were con-
sidered secondary BAs. The relative proportions of con-
jugated and de-conjugated forms of the moieties above were
determined. Conjugated BA, secondary BAs, primary Bas,
and the ratio of secondary to primary BAs were calculated
and compared between groups.
Cecal metabolites and ammonia metabolism. Serum ammo-
nia was measured using enzyme-linked immunosorbant
assay at Assaygate, Ijamsville, MD. Small-intestinal glutami-
nase activity was determined using the methods published in
Miller et al.,18 whereas cecal glutamine content and cecal
content amino-acid metabolomics were defined using GC-MS
at UC Davis after false-discovery rate-adjusted analysis of
variance for the named metabolites.18,19 Cecal contents were
used given its role as a major producer of microbially
produced metabolites.
Inflammatory expression and intestinal barrier study. We
studied intestinal barrier using (1) permeability assay (FITC-
Dextran mentioned above), (2) expression of large- and
small-intestinal zonulin and e-cadherin mRNA using quanti-
tative polymerase chain reaction with glyceraldehyde
3-phosphate dehydrogenase as the control, (3) intestinal
expression of IL-6, MCP-1, and IL-1β mRNA using quantita-
tive polymerase chain reaction with glyceraldehyde
3-phosphate dehydrogenase as the control. The systemic
inflammatory milieu was studied using serum IL-6 and IL-1β
measured using enzyme-linked immunosorbant assay at
Assaygate. Primers are noted in the Supplementary Data.
Statistical analysis. Comparisons were made between all
four groups as well as within groups 1 vs. 2 and groups 3 vs.
4 to define the impact of rifaximin in the GF and humanized
state. Kruskal–Wallis and analysis of variance were used as
appropriate using GraphPad Prism software (La Jolla, CA).
RESULTS
Mice freely consumed 100 mg/kg of rifaximin mixed in chow
without any adverse effects. We included sixteen 10–15-week
old C57BL/6 GF mice that were divided into four groups:
group 1, GF food controls; group 2, GF given rifaximin; group
3, humanized with stool from a cirrhotic patient; and group 4,
humanized with cirrhotic stool and given rifaximin (Figure 1).
All mice survived and were killed at day 30 without any
observable changes in behavior or activity. The cirrhosis stool
donor was a 47-year-old man with eradicated hepatitis c virus
cirrhosis with MHE who did not have prior decompensation.
His Model for End-Stage Liver Disease score was 12 and he
was not on antibiotics, rifaximin, lactulose, or proton-pump
inhibitors. His microbiota composition was similar to a group of
78 cirrhotic patients without decompensation (UNIFRAC
P= 0.12).2
Humanization with MHE patient’s stools resulted in
inflammation without change in ammonia. Microbial 16S
RNA relative abundance of stool and large intestine in groups
3 and 4 were similar to the donor (UNIFRAC weighted
P40.05, data not shown) indicating successful colonization.
In contrast, there was significantly higher endotoxemia, and
systemic and intestinal inflammatory mediators in the huma-
nized group. This was accompanied by a significantly reduced
intestinal expression of zonulin and e-cadherin (Table 1).
Rifaximin changes microbial functionality but not com-
position. There were no significant differences in the stool
(UNIFRAC weighted P= 0.72) or large-intestinal (P=0.4)
microbial composition between groups 3 and 4 or changes in
Chao1 diversity indices were seen (data not shown). On
LEFSe the only changes were an increase in relative
abundance of the families Porphyromonadaceae and lower
Erysipelothriceae in the rifaximin-treated humanized group. In
contrast to bacterial composition, functionality was signifi-
cantly affected. Endotoxin levels were negligible as expected
in GF groups. However, serum endotoxin significantly
increased after humanization, which was profoundly reduced
by rifaximin (Table 1).
Bile acids. Humanization and subsequent rifaximin therapy
had a profound impact on the fecal BA profile. As expected,
all BAs in the GF groups were tauro-conjugated and primary
BAs. Within the humanized groups, bacterial action was
evident by the detection of de-conjugated and secondary BA
moieties (Table 2). The addition of rifaximin significantly
reduced BA deconjugation and 7α de-hydroxylation in the
humanized mice. Conjugated BAs, secondary BAs, and the
secondary/primary BA ratio were significantly lower after
rifaximin therapy. This was also reflected in the lower cecal
taurine levels in the humanized+rifaximin group compared
with GF-rifaximin and humanized without rifaximin groups.
Ammonia levels and intestinal glutaminase activity are
lowered by rifaximin in GF mice. Serum ammonia was the
highest in GF mice due to increased small-intestinal
glutaminase activity, which was linked with a lower cecal
Figure 1 Schematic of study design.
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glutamine content (Figure 2,Table 3). Use of rifaximin (GF-
rifaximin) was associated with decreased intestinal glutami-
nase activity and an increase in glutamine and other cecal
amino-acid moieties compared with GF mice (Table 3).
Similarly, in humanized mice that were given rifaximin, when
compared with humanized mice alone, there was a reduction
in glutaminase activity with higher cecal glutamine and
correspondingly lower glutamate. This was accompanied by
changes in other amino-acid moieties related to the TCA
cycle (Supplementary Data). Serum ammonia levels con-
tinued to be low after humanization with the stools from the
MHE patient and rifaximin therapy did not have an impact on
the serum ammonia levels.
Intestinal barrier function and inflammation is differen-
tially affected with rifaximin. There was no change in
intestinal permeability between groups. Importantly, there was
no change in intestinal inflammatory cytokine expression,
intestinal zonulin, or e-cadherin in GF mice compared with GF
+rifaximin. After humanization with stool from the MHE patient,
there was a reduction in zonulin and e-cadherin, and increased
IL-6, IL-1β, and MCP-1 expression in the large and small
intestine compared with both GF groups. These changes were
significantly ameliorated with rifaximin therapy (Table 1).
Systemic pro-inflammatory milieu. Both GF animal groups
did not exhibit systemic inflammation and had evidence of low
IL-6, IL-1β, and endotoxin levels. These were statistically
similar with rifaximin treatment. However, after humanization
with stools from the MHE patient, there was a significant
increase in serum endotoxin, IL-6 and IL-1β levels compared
with GF groups. With the addition of rifaximin, these markers
were reduced significantly (Table 1).
Table 1 Changes in intestinal barrier function and inflammation
±S.e.m., GADPH ratio if units not specified GF (Gp 1) GF+rifaximin (Gp 2) Humanized (Gp 3) Humanized+rifaximin (Gp 4)
FITC-dextran 49.8± 2.3 59.0±2.7 48.3±3.0 62.5±7.4
Serum IL-1β (pg/ml) 11± 4 6±6 18±2* 7± 4‡
Serum IL-6 (pg/ml) 102± 34 83±23 185±23* 83± 23‡
Serum endotoxin (EU/ml) 0.01± 0.01 0.00±0.00 1.27±0.24*† 0.01± 0.02‡
Small-intestine MCP-1 2± 0.8 0.9±0.5 4±2*† 1.3± 0.5‡
Small-intestine IL-6 34± 9 42±19 109±38†* 68± 21‡
Small-intestine IL-1β 4.2± 1.1 3.8±1.3 9.3±1.9*† 3.5± 1.0‡
Small-intestine zonulin 0.5± 0.1 0.5±0.3 0.1±0.1*† 1.0± 0.3‡
Small-intestine e-cadherin 248.5± 52.3 212.8±6.4 108.9±18.4*† 246.1±37.4‡
Large-intestine MCP-1 4± 2 4±3 18±6*† 7± 3‡
Large-intestine IL-6 68± 34 58±29 166±123* 187± 117*
Large-intestine IL-1β 0.49± 0.15 0.40±0.18 1.57±0.14*† 0.34± 0.14‡
Large-intestine zonulin 0.49± 0.14 0.54±0.25 0.12±0.11*† 1.0±0.33‡
Large-intestine e-cadherin 295.0± 27.2 239.6±47.7 78.8±34.9* 189.2±21.2‡
†Po0.05 group 3 vs. others.
*Po0.05 compared with group 1.
‡Po0.05 group 4 vs. 3.
Table 2 Fecal bile acids in the mouse groups
Median (IQR), μmol/g feces GF (Gp 1) GF+rifaximin (Gp 2) Humanized (Gp 3) Humanized+rifaximin (Gp 4)
Total fecal BA 1.94 (0.38) 2.12 (0.64) 1.5 (0.16)† 1.93 (0.45)
Total primary BAs (conjugated+unconjugated
moieties)
1.89 (0.39) 2.02 (0.69) 1.33 (0.16)* 1.80 (0.44)
Total conjugated primary BAs 1.89 (0.39) 2.02 (0.69) 0.16 (0.08)* 0.23 (0.08)*
Tauro-cholic acid 0.34 (0.05) 0.37 (0.15) 0.11 (0.03) 0.14 (0.06)
Tauro-chenodeoxycholic acid 0.01 (0.05) 0.01 (0.01) 0.0 0.0
Tauro α-muricholic acid 0.04 (0.01) 0.04 (0.01) 0.0 0.0
Tauro β-muricholic acid 1.15 (0.34) 1.60 (0.47) 0.07 (0.03) 0.09 (0.03)
Total unconjugated primary BAs 0.0 0.0 1.2 (0.1)* 1.6 (0.5)‡*
Chenodeoxycholic acid 0.0 0.0 0.0 0.0
Cholic Acid 0.0 0.0 0.03 (0.01)* 0.06 (0.05)*
α-Muricholic acid 0.0 0.0 0.05 (0.0)* 0.04 (0.02)*
β-Muricholic acid 0.0 0.0 1.07 (0.1)* 1.4 (0.4)*
Total secondary BAs 0.0 0.0 0.15 (0.04)†* 0.06 (0.03)‡*
Deoxycholic acid 0.0 0.0 0.11 (0.04)†* 0.04 (0.09)*
Lithocholic acid 0.0 0.0 0.01 (0.01) 0.0
ω-Muricholic acid 0.0 0.0 0.02 (0.0) 0.02 (0.0)
Secondary/primary BA ratio 0.0 0.0 0.12 (0.04)* 0.03 (0.06)‡*
†Po0.05 group 3 vs. others.
*Po0.05 compared with group 1.
‡Po0.05 group 4 vs. 3.
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DISCUSSION
Our results indicate that rifaximin impacts intestinal ammonia
generation and cecal amino-acid profiles even in the absence
of microbiota in GF mice. After humanization, it can favorably
impact bacterial function without significantly affecting stool or
large-intestinal bacterial composition. We also found that
humanization of GF mice with stools from a patient with MHE
results in changes in intestinal barrier function and systemic
inflammation without hyperammonemia or development of
liver disease, which is improved after rifaximin therapy.
In patients with HE, ammonia generation can occur through
gut dysbiosis, or through small-bowel glutaminase that cleaves
dietary glutamine into ammonia and glutamate.20 In end-stage
liver disease and cirrhosis, this can beworsened by an impaired
urea cycle. It is hypothesized that ultimately, HE results from the
combination of hyperammonemia, porto-systemic shunting,
and systemic inflammation.21 The role of rifaximin inmodulating
outcomes, presumably through its antibiotic action, has been
studied in humans with HE with the finding of only modest
changes in overall microbiota composition.2,3 However, we did
not use classic animal models for HE or hyperammonemia as
our aim was to evaluate the microbial contribution alone to this
disease and the response to rifaximin.22
Our results demonstrate that the beneficial effect of rifaximin
therapy on intestinal ammonia generation can occur in the
absence of microbiota, indicating a direct effect of rifaximin on
the host. The suppression of small-bowel glutaminase, with a
resultant increase in cecal glutamine content in both GF and
humanized states indicates the ability of rifaximin to impact
host ammonia generation through means unrelated to its
action on gut microbiota. This was also accentuated by the
increase in cecal amino acids related to the urea cycle in GF
mice treated with rifaximin. Intestinal inflammation and barrier
function was not significantly impacted by rifaximin in the
absence of intestinal bacteria, likely due to the lack of intestinal
inflammatory cytokine expression and permeability issues at
baseline in GF mice.
An interesting dichotomy between intestinal/systemic
inflammatory markers and ammonia was observed when the
humanized and GF mice were compared. In the mice
humanized with stools from an MHE patient, there was
evidence of intestinal inflammatory marker activation with
systemic inflammation and endotoxemia without increase in
ammonia, whereas the opposite was seen in GF mice due to
activation of intestinal glutaminase activity.23 We chose to
study humanization of GF mice to isolate the impact of
microbiota on systemic and intestinal inflammation and
ammonia generation, in the absence of liver disease and
porto-systemic shunting. The impact of rifaximin, which is a
non-absorbable compound, then could be tested on the gut
microbial milieu without confounding effects related to liver
disease and shunting that it cannot directly impact. We used
the stool from a single, well-characterized donor similar to a
recent study to avoid confounding from a larger donor pool.24
We also did not use stool from a healthy human as a control
because prior studies have not demonstrated intestinal
inflammation in mice simply by humanization25 and because
our focus remained on the impact of rifaximin on MHE-
associated microbiota. We also did not use stools of a patient
with prior/current overt HE given that these patients are
typically on lactulose and/or rifaximin therapy, and their stool
transfer could have confounded results.11 The results after
humanization suggest that although microbial transfer is able
to cause local gut and systemic inflammatory changes,
concomitant liver disease and shunting appears be required
to induce hyperammonemia in this setting.
Figure 2 Ammonia changes after rifaximin. (a) Serum ammonia levels were
significantly lower in all three groups compared with GF mice. No significant
difference in ammonia levels were seen after rifaximin in the humanized mice. (b)
Small-intestinal glutaminase expression was significantly lowered by rifaximin in both
groups. (c) There was a significant increase in glutamine levels (retention index on
GC-MS) after rifaximin in both groups. GF, germ-free; MHE-Hum, humanized with
stool from a patient with minimal hepatic encephalopathy stool; rif, rifaximin.
*Po0.05, **Po0.01.
Rifaximin Reduces Ammonia Even in Germ-free Conditions
Kang et al.
5
Clinical and Translational Gastroenterology
We found a significant improvement in systemic and
intestinal inflammatory cytokines with important effects on the
cecal metabolic milieu after rifaximin treatment of humanized
mice. After rifaximin, humanized mice showed a significant
increase in cecal glutamine with corresponding decrease in
glutamate, likely due to the accompanying suppression of
intestinal glutaminase. There was an increase in cecal gamma-
amino butyric acid and α-ketoglutarate, which can result in the
formation of succinic acid that goes into the Kreb’s cycle with
citrate formation and improves bio-energetics.
The divergent impact of rifaximin on gut microbial function
but not significantly on composition is interesting. Important
functional changes after rifaximin spanned many processes
ranging from those that most gut bacteria possess, i.e., BA
deconjugation, to specialized properties restricted to Gram-
negative bacteria, i.e., reduced endotoxemia, and the ability of
Gram-positive anaerobes to mediate the conversion from
primary to secondary Bas.26 BA alterations can in turn
regulate gut microbial function and composition.27 This role
of rifaximin modulating bacterial behavior independent of its
antibiotic activities fosters a potentially beneficial gut milieu
that could then enhance the intestinal barrier function.
The complex gut barrier was partly improved with rifaximin
as it improved inflammatory mediators, and expression of
zonulin and e-cadherin in humanized mice but did not affect
mucosal permeability. These results partly replicate improve-
ments in intestinal function seen with rifaximin in mice with
chronic stress.28 Humanization with stool from MHE induced
relatively subtle changes in intestinal barrier function, without
significantly impacting permeability, which could be why
rifaximin improved all other studied aspects of intestinal
barrier function. Although themechanism behind this improve-
ment is not completely clear, the reduction in secondary BAs
could be a potential contributing factor.29 Other studies have
also highlighted the role of rifaximin in reducing inflammation
and attenuating the impact of endotoxin on the intestinal
barrier by activating the pregnane X receptor.30,31 The
combination of reduced endotoxin, and secondary BAs and
potential pregnane X receptor activation, in the setting of
favorable cecal bio-energetics, could contribute to the overall
beneficial impact of rifaximin. These changes in gut bacterial
and intestinal barrier function can have important downstream
consequences in the liver and on visceral hyperalgesia, as
shown in prior conventional animal studies with rifaximin.28,32
The study is limited by the sample size, which reduced our
ability to detect subtle changes in the mechanism of action for
rifaximin. In addition, the mice humanized with stool from the
MHE patient did not develop liver disease or significant
hyperammonemia in our model. However, the changes in
ammonia are unlikely due to sources other than small-
intestinal glutaminase activity given that the diet was identical
in all groups and none of the mice developed liver disease that
could have substantially impaired ureagenesis. Our findings
with the transfer of the MHE patient’s stool indicate that the
microbiota alone may have a limited impact in the absence of
liver disease on overall inflammation. Conversely, a recent
study shows that cirrhosis in the GF state does not lead to
systemic, intestinal, or neuro-inflammation despite hyperam-
monemia.33 Therefore, both an altered microbiota and
concomitant liver disease may be required for the pro-
inflammatory milieu in cirrhosis. These findings set the stage
for further studies to evaluate the role of rifaximin in the
presence of hyperammonemia and liver disease with other
human donors and in conventionally raised mice.
The study findings of inflammation induced with humaniza-
tion with MHE patient’s stool could have benefited with
comparison with healthy stool-associated humanization.
However, prior studies have shown that there is minimal
inflammation with changeswith healthy stool in GFmice25 and
the focus of this study was the changes caused by rifaximin on
MHE-associated microbiota. Ultimately, further studies with
larger number of mouse groups in the GF and conventional
states are needed to evaluate these mechanisms further.
We conclude that the effects of rifaximin on intestinal
ammonia metabolism, systemic, and intestinal inflammatory
mediators are multi-faceted and are only partly related to its
role as an antibiotic.
CONFLICT OF INTEREST
Guarantor of the article: Jasmohan S. Bajaj, MD.
Specific author contributions: Conceptualized the study
and were involved in all aspects: Jasmohan S. Bajaj and R.
Balfour Sartor, involved in animal experiments: Dae J. Kang,
Jeremy Herzog, Ian Carroll, Chunhua Jiao, and Jing Yang;
involved in Bile acid analysis: Genta Kakiyama, Hiroshi
Nittono, Hajime Takei, Takashi Iida, and Takao Kurosawa;
involved in microbiota analysis: Patrick M. Gillevet, Naga S.
Betrapally, and Masoumeh Sikaroodi; involved in
metabolomics analysis: Sili Fan and Oliver Fiehn; critically
revised the manuscript: Huiping Zhou, Douglas M. Heuman,
and Phillip B. Hylemon.
Financial support: This research was partly supported by VA
Merit review CX10076 and NIDDK RO1DK089713 (J.S.B.) and
Table 3 Cecal content metabolomics changes between groups after rifaximin
Groups GF vs. GF+rifaximin Humanized vs. humanized+rifaximin
Comparison ↑/↓: higher/lower in GF+rifaximin group ↑/↓: higher/lower in humanized+rifaximin group
Metabolites different between groups Glutamine↑ Glutamine↑
Ornithine↑ Glutamate↓
Citrulline↑ GABA↑
N-acetyl-glutamate↑ Alpha-ketoglutarate↑
Cysteine↑ Succinic acid↑
Lysine↑ Proline↑
Citrate↑
Taurine↓
Rifaximin Reduces Ammonia Even in Germ-free Conditions
Kang et al.
6
Clinical and Translational Gastroenterology
NIH grants P40 OD010995, P30 DK034987, the Crohn’s and
Colitis Foundation of America (RBS for National Gnotobiotic
Rodent Resource Center) and an investigator-initiated grant
from Valeant Pharmaceuticals (J.S.B. and R.B.S.).
Potential competing interests:R.B.S. and J.S.B. have served
as consultants with Valeant Pharmaceuticals. The remaining
authors declare no conflict of interest.
Acknowledgments. We acknowledge the staff of NGRRC, especially
Maureen Bower, RN for their assistance.
Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓ Rifaximin is beneficial clinically in patients with overt and
minimal hepatic encephalopathy.
✓ It is assumed that its antibiotic action is the main
mechanism of action.
✓ The role of rifaximin independent of microbiota is unclear.
WHAT IS NEW HERE
✓ Rifaximin reduced the generation of ammonia through
reduction in intestinal glutaminase activity and modulation
of the cecal amino-acid milieu in germ-free mice.
✓ When germ-free mice were colonized with stool from a
patient with minimal hepatic encephalopathy, there was
evidence of endotoxemia, systemic inflammation, and
impaired intestinal inflammatory cytokine and barrier
protein expression, but not hyperammonemia.
✓ In these humanized mice, rifaximin reduced intestinal and
systemic inflammatory markers, and also favorably
impacted microbiota functionality through reduced de-
conjugated and secondary bile acids, and decreased
endotoxemia, without changes in bacterial relative
abundance.
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